October 2012, 2:56,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 03 Oct 2012
Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
Positron emission tomography (PET) may be useful for defining the gross tumour volume for radiation treatment planning and for response monitoring of non-small cell lung cancer (NSCLC) patients. The purpose of this study was to compare tumour sizes obtained from CT- and various more commonly available PET-based tumour delineation methods to pathology findings.
Retrospective non-respiratory gated whole body [18F]-fluoro-2-deoxy-D-glucose PET/CT studies from 19 NSCLC patients were used. Several (semi-)automatic PET-based tumour delineation methods and manual CT-based delineation were used to assess the maximum tumour diameter.
50%, adaptive 41% threshold-based and contrast-oriented delineation methods showed good agreement with pathology after removing two outliers (R2=0.82). An absolute SUV threshold of 2.5 also showed a good agreement with pathology after the removal of 5 outliers (R2: 0.79), but showed a significant overestimation in the maximum diameter (19.8 mm, p<0.05). Adaptive 50%, relative threshold level and gradient-based methods did not show any outliers, provided only small, non-significant differences in maximum tumour diameter (<4.7 mm, p>0.10), and showed fair correlation (R2>0.62) with pathology. Although adaptive 70% threshold-based methods showed underestimation compared to pathology (36%), it provided the best precision (SD: 14%) together with good correlation (R2=0.81). Good correlation between CT delineation and pathology was observed (R2=0.77). However, CT delineation showed a significant overestimation compared with pathology (3.8 mm, p<0.05).
PET-based tumour delineation methods provided tumour sizes in agreement with pathology and may therefore be useful to define the (metabolically most) active part of the tumour for radiotherapy and response monitoring purposes.
Erdi YE: The use of PET for radiotherapy. Current Medical Imaging Reviews 2007, 3:3–16.
van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, hing-Oberije C, Houben R, et al.: PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007, 68:771–778.PubMedCrossRef
Petit SF, van Elmpt WJ, Oberije CJ, Vegt E, Dingemans AM, Lambin P, Dekker AL, De RD: [(18)F]fluorodeoxyglucose Uptake Patterns in Lung Before Radiotherapy Identify Areas More Susceptible to Radiation-Induced Lung Toxicity in Non-Small-Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2010.
Schaefer A, Kremp S, Hellwig D, Rube C, Kirsch CM, Nestle U: A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging 2008, 35:1989–1999.PubMedCrossRef
Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA: Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004, 45:1519–1527.PubMed
Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp L, Uitterhoeve AL, Rodrigus PT, Kramer GW, Bussink J, De Jaeger K, et al.: Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation. Radiother Oncol 2005, 77:182–190.PubMedCrossRef
- Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- October 2012
- Online ISSN
- Additional Links
- Tumour delineation
- Tumour diameter
- FDG PET
- Non-small cell lung cancer
- Author Affiliations
- 1. Department of Radiology & Nuclear Medicine, VU University Medical Center, PO Box 7057, Amsterdam, 1007MB, The Netherlands
- 2. Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands